| scholarly article | Q13442814 |
| P356 | DOI | 10.1038/S41582-019-0301-2 |
| P698 | PubMed publication ID | 31980808 |
| P50 | author | Eduardo Tolosa | Q92933186 |
| P2093 | author name string | Christine Klein | |
| Olivier Rascol | |||
| Miquel Vila | |||
| P2860 | cites work | The role of Rab GTPases in the pathobiology of Parkinson' disease | Q64767459 |
| Caught in the act: LRRK2 in exosomes | Q64777632 | ||
| The unlikely partnership between LRRK2 and α-synuclein in Parkinson's disease | Q64859135 | ||
| The genetic landscape of Parkinson's disease | Q64859339 | ||
| Parkinson's disease due to the R1441G mutation in Dardarin: a founder effect in the Basques | Q80314487 | ||
| Synthesis and Preliminary Evaluation of [11 C]GNE-1023 as a Potent PET Probe for Imaging Leucine-Rich Repeat Kinase 2 (LRRK2) in Parkinson's Disease | Q92314123 | ||
| Meta-analysis of early nonmotor features and risk factors for Parkinson disease | Q22252935 | ||
| Genome-wide association study reveals genetic risk underlying Parkinson's disease | Q24646654 | ||
| Is inhibition of kinase activity the only therapeutic strategy for LRRK2-associated Parkinson's disease? | Q27026262 | ||
| Phosphoproteomics reveals that Parkinson's disease kinase LRRK2 regulates a subset of Rab GTPases | Q28119192 | ||
| Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology | Q28131833 | ||
| Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease | Q28244731 | ||
| Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease | Q28292932 | ||
| Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease | Q29614900 | ||
| Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study | Q29614953 | ||
| Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial. | Q30357397 | ||
| Echogenicity of the substantia nigra: association with increased iron content and marker for susceptibility to nigrostriatal injury | Q33183795 | ||
| Brain iron chelation by deferiprone in a phase 2 randomised double-blinded placebo controlled clinical trial in Parkinson's disease. | Q33684033 | ||
| LRRK2 levels in immune cells are increased in Parkinson's disease | Q33765746 | ||
| LRRK2 parkinsonism in Tunisia and Norway: a comparative analysis of disease penetrance. | Q34079325 | ||
| A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2-q13.1. | Q34118222 | ||
| Leucine-rich repeat kinase 2 for beginners: six key questions. | Q34259058 | ||
| Nonmotor symptoms in LRRK2 G2019S associated Parkinson's disease | Q34361735 | ||
| MDS research criteria for prodromal Parkinson's disease | Q34498279 | ||
| Imaging prodromal Parkinson disease: the Parkinson Associated Risk Syndrome Study | Q34553777 | ||
| Neuropsychological performance in LRRK2 G2019S carriers with Parkinson's disease | Q35013928 | ||
| Reorganization of corticostriatal circuits in healthy G2019S LRRK2 carriers | Q35106295 | ||
| Phenotype in parkinsonian and nonparkinsonian LRRK2 G2019S mutation carriers | Q35119612 | ||
| LRRK2 protein levels are determined by kinase function and are crucial for kidney and lung homeostasis in mice | Q35288337 | ||
| Clinical correlations with Lewy body pathology in LRRK2-related Parkinson disease | Q35442728 | ||
| Sleep Disorders in Parkinsonian and Nonparkinsonian LRRK2 Mutation Carriers | Q35692655 | ||
| Nonmotor symptoms in healthy Ashkenazi Jewish carriers of the G2019S mutation in the LRRK2 gene | Q35772821 | ||
| MicroRNA-205 regulates the expression of Parkinson's disease-related leucine-rich repeat kinase 2 protein. | Q36525872 | ||
| Parkinson disease phenotype in Ashkenazi Jews with and without LRRK2 G2019S mutations | Q37385032 | ||
| Diagnosis and the premotor phase of Parkinson disease | Q37394473 | ||
| Submandibular gland needle biopsy for the diagnosis of Parkinson disease | Q37648832 | ||
| Genetic Analysis of Pathways to Parkinson Disease | Q37801078 | ||
| Milestones in PD genetics | Q37882589 | ||
| The neuropathology of genetic Parkinson's disease | Q37997386 | ||
| Challenges of modifying disease progression in prediagnostic Parkinson's disease | Q38780987 | ||
| Challenges in detecting disease modification in Parkinson's disease clinical trials | Q38799420 | ||
| The prodromal phase of leucine-rich repeat kinase 2-associated Parkinson disease: Clinical and imaging Studies | Q38859352 | ||
| Clinical Features of LRRK2 Carriers with Parkinson's Disease | Q39206423 | ||
| Targeting LRRK2 in Parkinson's disease: an update on recent developments | Q39263032 | ||
| Motor phenotype of LRRK2-associated Parkinson's disease: a Tunisian longitudinal study | Q39288784 | ||
| A comparative study of LRRK2, PINK1 and genetically undefined familial Parkinson's disease | Q39305573 | ||
| Nigral and striatal connectivity alterations in asymptomatic LRRK2 mutation carriers: A magnetic resonance imaging study | Q39366467 | ||
| Neural correlates of executive functions in healthy G2019S LRRK2 mutation carriers | Q39477657 | ||
| Ser(P)-1292 LRRK2 in urinary exosomes is elevated in idiopathic Parkinson's disease | Q39686532 | ||
| Motor and nonmotor heterogeneity of LRRK2-related and idiopathic Parkinson's disease | Q39841718 | ||
| Conformational heterogeneity of the Roc domains in C. tepidum Roc-COR and implications for human LRRK2 Parkinson mutations | Q40604356 | ||
| LRRK2 mutations in Parkinson disease; a sex effect or lack thereof? A meta-analysis | Q40952048 | ||
| Arm swing as a potential new prodromal marker of Parkinson's disease | Q41355527 | ||
| LRRK2 Antisense Oligonucleotides Ameliorate α-Synuclein Inclusion Formation in a Parkinson's Disease Mouse Model | Q41539639 | ||
| Clinical and brain imaging characteristics in leucine-rich repeat kinase 2-associated PD and asymptomatic mutation carriers | Q42495787 | ||
| Penetrance in Parkinson's disease related to the LRRK2 R1441G mutation in the Basque country (Spain). | Q42933007 | ||
| The G2019S LRRK2 mutation is uncommon in an Asian cohort of Parkinson's disease patients. | Q43560873 | ||
| Prospective clinical and DaT-SPECT imaging in premotor LRRK2 G2019S-associated Parkinson disease | Q44060284 | ||
| Clinical features of LRRK2-associated Parkinson's disease in central Norway | Q44830290 | ||
| Simvastatin as a Potential Disease-Modifying Therapy for Patients with Parkinson's Disease: Rationale for Clinical Trial, and Current Progress | Q45201060 | ||
| Penetrance estimate of LRRK2 p.G2019S mutation in individuals of non-Ashkenazi Jewish ancestry. | Q46001147 | ||
| Olfactory deficits and cardiac 123I-MIBG in Parkinson's disease related to the LRRK2 R1441G and G2019S mutations | Q46521682 | ||
| Effect of selective LRRK2 kinase inhibition on nonhuman primate lung. | Q46777308 | ||
| Clinical profiles of Parkinson's disease associated with common leucine-rich repeat kinase 2 and glucocerebrosidase genetic variants in Chinese individuals | Q46940068 | ||
| LRRK2 mutations in Spanish patients with Parkinson disease: frequency, clinical features, and incomplete penetrance | Q46988538 | ||
| Systematic proteomic analysis of LRRK2-mediated Rab GTPase phosphorylation establishes a connection to ciliogenesis. | Q47142767 | ||
| Progression in the LRRK2-Asssociated Parkinson Disease Population | Q47198236 | ||
| Selective α-Synuclein Knockdown in Monoamine Neurons by Intranasal Oligonucleotide Delivery: Potential Therapy for Parkinson's Disease. | Q47259722 | ||
| A meta-analysis of genome-wide association studies identifies 17 new Parkinson's disease risk loci. | Q47823702 | ||
| Assessment of α-synuclein in submandibular glands of patients with idiopathic rapid-eye-movement sleep behaviour disorder: a case-control study. | Q47871750 | ||
| DAT imaging and clinical biomarkers in relatives at genetic risk for LRRK2 R1441G Parkinson's disease. | Q47907932 | ||
| Sleep aspects on video-polysomnography in LRRK2 mutation carriers | Q47927139 | ||
| Clinical and neuropathological features of progressive supranuclear palsy in Leucine rich repeat kinase (LRRK2) G2019S mutation carriers | Q47978229 | ||
| Achieving neuroprotection with LRRK2 kinase inhibitors in Parkinson disease | Q48003270 | ||
| Nigral anatomy and striatal denervation in genetic Parkinsonism: A family report | Q48118182 | ||
| Synthesis and In Vitro and In Vivo Evaluation of [3H]LRRK2-IN-1 as a Novel Radioligand for LRRK2. | Q48132251 | ||
| Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial | Q48164658 | ||
| Structural imaging in the presymptomatic stage of genetically determined parkinsonism | Q48193304 | ||
| Olfaction and imaging biomarkers in premotor LRRK2 G2019S-associated Parkinson disease | Q48206843 | ||
| Mechanisms of Mutant LRRK2 Neurodegeneration | Q48239635 | ||
| How does parkinsonism start? Prodromal parkinsonism motor changes in idiopathic REM sleep behaviour disorder | Q48245989 | ||
| Cerebral pathological and compensatory mechanisms in the premotor phase of leucine-rich repeat kinase 2 parkinsonism | Q48248911 | ||
| Ser1292 autophosphorylation is an indicator of LRRK2 kinase activity and contributes to the cellular effects of PD mutations | Q48252778 | ||
| Serial dopamine transporter imaging of nigrostriatal function in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study | Q48290740 | ||
| Cognitive and behavioral symptoms in Parkinson's disease patients with the G2019S and R1441G mutations of the LRRK2 gene. | Q50593282 | ||
| Synthesis of [11C]HG-10-102-01 as a new potential PET agent for imaging of LRRK2 enzyme in Parkinson's disease | Q50880166 | ||
| Application of the Movement Disorder Society prodromal criteria in healthy G2019S-LRRK2 carriers | Q51758052 | ||
| Disease modification in Parkinson's Disease: Current approaches, challenges, and future considerations | Q52691106 | ||
| LRRK2 is a negative regulator of Mycobacterium tuberculosis phagosome maturation in macrophages | Q54107836 | ||
| Leucine-Rich Repeat Kinase 2 in Parkinson's Disease: Updated from Pathogenesis to Potential Therapeutic Target | Q54113701 | ||
| Targeted therapies for Parkinson's disease: From genetics to the clinic | Q54113831 | ||
| LRRK2 kinase in Parkinson's disease | Q54117350 | ||
| LRRK2 G2019S and R1441G mutations associated with Parkinson's disease are common in the Basque Country, but relative prevalence is determined by ethnicity. | Q54786905 | ||
| LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews. | Q55041570 | ||
| Genetic background and outcome of Deep Brain Stimulation in Parkinson's disease | Q57170148 | ||
| Genotype-phenotype relations for the Parkinson's disease genes SNCA, LRRK2, VPS35: MDSGene systematic review | Q57793426 | ||
| New Frontiers in Parkinson's Disease: From Genetics to the Clinic | Q58089204 | ||
| LRRK2G2019S as a Cause of Parkinson's Disease in North African Arabs | Q58489573 | ||
| Magnetic resonance T1w/T2w ratio: A parsimonious marker for Parkinson's disease | Q58574554 | ||
| LRRK2 activation in idiopathic Parkinson's disease. | Q60143544 | ||
| Dermal Phospho-Alpha-Synuclein Deposition in Patients With Parkinson's Disease and Mutation of the Glucocerebrosidase Gene | Q60951154 | ||
| Investigating Voice as a Biomarker for Leucine-Rich Repeat Kinase 2-Associated Parkinson’s Disease | Q62664872 | ||
| LRRK2 inhibition does not impart protection from α-synuclein pathology and neuron death in non-transgenic mice | Q64098788 | ||
| P433 | issue | 2 | |
| P921 | main subject | Parkinson's disease | Q11085 |
| P304 | page(s) | 97-107 | |
| P577 | publication date | 2020-01-24 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Nature Reviews Neurology | Q2079285 |
| P1476 | title | LRRK2 in Parkinson disease: challenges of clinical trials | |
| P478 | volume | 16 |
| Q97905661 | Aspirin and ibuprofen could lower risk of LRRK2 Parkinson disease |
| Q99248256 | CHIP as a therapeutic target for neurological diseases |
| Q94586208 | CSF total and oligomeric α-Synuclein along with TNF-α as risk biomarkers for Parkinson's disease: a study in LRRK2 mutation carriers |
| Q104504601 | LRRK2 and survival in progressive supranuclear palsy |
| Q100559468 | Mitochondrial DNA damage as a potential biomarker of LRRK2 kinase activity in LRRK2 Parkinson's disease |
| Q94560848 | Mitochondrial Homeostasis and Signaling in Parkinson's Disease |
| Q99572138 | Unique roles of rare variants in the genetics of complex diseases in humans |
| Q90681446 | WGCNA analysis of the subcutaneous fat transcriptome in a novel tree shrew model |
Search more.